Rgenix Appoints Chief Medical Officer

April 27, 2017 07:00 AM Eastern Daylight Time

NEW YORK--(BUSINESS WIRE)--Rgenix, Inc., a clinical stage biopharmaceutical company developing
first-in-class small molecule and antibody cancer therapeutics,
announced today the appointment of Roger Waltzman, M.D., M.B.A. as its
Chief Medical Officer. Dr. Waltzman brings more than 20 years of
experience in oncology across the entire new drug development and
approval process, including serving in various executive roles at
Novartis for nearly a decade.

In his role, he will oversee clinical development at Rgenix, including
clinical trial design and the new drug application process with
regulators. He will also support Rgenix’s goals of providing a
meaningful response for cancer patients lacking effective therapies by
overseeing the patient experience.

“Dr. Waltzman has an extraordinary background in oncology, which is our
focus at Rgenix, and his expertise will be crucial as we progress with
the clinical development of our lead therapy, RGX-104, and our other
drug candidates in development,” said Masoud Tavazoie, M.D., Ph.D.,
Chief Executive Officer and co-founder of Rgenix. “We look forward to
his contributions to our work at Rgenix as we develop novel treatments
for patients who suffer from cancer types with a high, unmet need.”

“Rgenix has innovation at its core, and I’m pleased to be joining an
organization that is looking to fill a gap in oncology that could
benefit hundreds of thousands of patients. I look forward to
collaborating with the Rgenix team on its therapies and clinical
developments as it looks to drive positive change in the industry,” said
Dr. Waltzman.

Prior to Rgenix, Dr. Waltzman worked at Novartis in both Medical Affairs
and Clinical Development roles. In oncology, he successfully filed an
sNDA as the Clinical Development Head for Tasigna/Glivec and led the
successful development and MAA/NDA filing of Jakavi/Jakafi, in
collaboration with Incyte. His last position at Novartis was as Global
Development Head for anti-malarials, where he continued Phase 2
development of two novel anti-malarials and facilitated a cost-saving
Collaboration Agreement with the Bill and Melinda Gates Foundation and
Medicines for Malaria Venture.

His most recent position was with Jaguar Animal Health and Napo
Pharmaceuticals in San Francisco where he was the Chief Scientific
Officer and Chief Medical Officer, leading the development of a
first-in-class, FDA-approved botanical as a novel anti-diarrheal.

Dr. Waltzman received his medical degree from Brown University School of
Medicine and his MBA from Columbia Business School. He completed his
residency in Internal Medicine at Harvard’s Beth Israel Hospital, and
his fellowship in hematology/oncology at Memorial Sloan-Kettering Cancer
Center. He has been a member of the board of directors of GoDocGo and
the Brown Medical Alumni Association since 2015.

About Rgenix

Rgenix, Inc., is a privately-held clinical-stage biopharmaceutical
company focused on the discovery and development of novel cancer drugs
that target key pathways in cancer progression. Using a miRNA based
target discovery platform developed by Rgenix’s founders at The
Rockefeller University, the company is pursuing several first-in-class
drug candidates to treat cancers of high unmet need. The company brings
together distinguished scientific founders, a seasoned Board, and a
leadership team comprised of experienced drug developers. The company is
funded by leading biotechnology investors, including Novo A/S, Sofinnova
Partners, and Alexandria Venture Investments. For more information,
please visit www.rgenix.com.